Summary
It could be said mesenchymal stem cells (MSC) haven’t lived up to their promise of transforming clinical outcomes through regeneration of tissues. That is not to say they don’t have an effect in healing and, as such, not necessarily an indictment of MSC’s themselves, but a function of the realization any wound or regenerative healing environment is a very complex niche which needs to be addressed as a system. With that said, it seems to be understood the paracrine effects of implanted MSC’s are one component to their therapeutical benefit which may create an opportunity to harness that effect for drug delivery. This article explores that possibility in a DFU environment.
Did you find this helpful?
Thank you for your feedback!
